BofA analyst Matthew DeYoe raised the firm’s price target on Albemarle to $212 from $200 and keeps a Neutral rating on the shares after the company reported Q2 EBITDA that was “well ahead” of the $725M consensus forecast. Oversupply in the lithium market is “likely to test producer discipline and force higher cost operations out of the market,” which will “likely be a difficult backdrop” for Albemarle equity performance, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALB:
- Albemarle price target raised to $227 from $225 at Mizuho
- Albemarle price target raised to $185 from $163 at Credit Suisse
- Albemarle raises FY23 adjusted EPS view to $25.00-$29.50 from $20.75-$25.75
- Albemarle Reports Net Sales Increase of 60% for Second Quarter 2023
- Albemarle reports Q2 adjusted EPS $7.33, consensus $4.44